SCHEMBL893929

SCHEMBL893929

NCc1cc(-c2ccc(C(F)(F)F)cc2)nc(-c2cccnc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.51
NPC1 O15118 2/20 0.48
NPY5R Q15761 1/20 0.45
DGAT1 O75907 1/20 0.44
KCNH2 Q12809 1/20 0.44
DPP4 P27487 1/20 0.44
TOP1 P11387 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CYP2A6 P11509 3/20 0.42
SCN9A Q15858 1/20 0.41
CYP2C19 P33261 3/20 0.41
CYP3A4 P08684 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3721220 0.85 KIF11 (0.51) S1PR1NPC1DPP4TOP1RAB9A
SCHEMBL3725421 0.85 DPP4 (0.50) DPP4TOP1KDM4EALDH1A1SCN9A
SCHEMBL3567928 0.84 S1PR1 (0.56) S1PR1NPC1NPY5RDGAT1KCNH2
SCHEMBL3718641 0.83 DPP4 (0.47) NPC1KCNH2DPP4RAB9ACTSS
SCHEMBL25459772 0.82 S1PR1 (0.53) S1PR1NPC1NPY5RDGAT1KCNH2
SCHEMBL30085885 0.82 S1PR1 (0.53) S1PR1NPC1NPY5RDGAT1KCNH2
SCHEMBL3718626 0.80 KDM4E (0.61) KDM4EALDH1A1SMN1; SMN2CYP2C19CYP3A4
SCHEMBL3728860 0.79 SCN9A (0.56) S1PR1NPC1SMN1; SMN2SCN9ALMNA
SCHEMBL893956 0.79 KMT2A (0.45) S1PR1NPC1NPY5RDGAT1KCNH2
SCHEMBL3721250 0.78 KDM4E (0.50) NPC1KDM4EALDH1A1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614201-B2 Heterocyclic amides as modulators of TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2013-12-24 US claimed
WO-2010141805-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 WO claimed
US-8614201-B2 Heterocyclic amides as modulators of TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2013-12-24 US disclosed
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 US disclosed
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 US disclosed
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 US disclosed
WO-2010141805-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 WO disclosed
WO-2010141805-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 TRPA1, TRPV1, TRPV2 S1PR1 1742/4885NPC1 951/4885NPY5R 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.